AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Otofarma S.p.A.

Share Issue/Capital Change Sep 8, 2025

14882_rns_2025-09-08_9539fd95-fe2c-458d-a623-f8a5ba07d717.pdf

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Informazione
Regolamentata n.
20343-10-2025
Data/Ora Inizio Diffusione
8 Settembre 2025 17:49:11
Euronext Growth Milan
Societa' : OTOFARMA
Identificativo Informazione
Regolamentata
: 209751
Utenza - referente : OTOFARMAESTN01 - Anna Incarnato
Bartolomucci
Tipologia : 2.5
Data/Ora Ricezione : 8 Settembre 2025 17:49:11
Data/Ora Inizio Diffusione : 8 Settembre 2025 17:49:11
Oggetto : OTOFARMA: announcement of change in
share capital following full exercise of
greenshoe option

Testo del comunicato

Vedi allegato

Press release

OTOFARMA: announcement of change in share capital following full exercise of greenshoe option

Naples, 8 September 2025 – The Otofarma Group – with over 30 years of experience in the hearing care sector and a leading manufacturer of hearing aids distributed mainly through the pharmaceutical channel – announces the new composition of its share capital following the issue of 190,500 ordinary shares of the Company relating to the full exercise of the Greenshoe Option in the capital increase (see press release of 2 September 2025) by Alantra Capital Markets S.A.U., Italian Branch (hereinafter also "Alantra"), granted by shareholder Bartolomucci Holding S.r.l. during the placement of its ordinary shares on the Euronext Growth Milan ("EGM") market.

The new composition of Otofarma's share capital (fully subscribed and paid up) following the filing of the certificate of change in share capital with the competent Companies Register of Naples is shown below:

Current Share Capital Previous Share Capital Change
Euro No. Shares Nom. Value. Euro No. Shares Nom. Value. Euro No.
Shares
Nom.
Value.
Total,
of
which
1,635,484.47 5,947,000 shares with
no par value
1,583,095 5,756,500 shares with
no par
value
52,389 190,500 shares
with no
par
value
Ordinary
shares
1,635,484.47 5,947,000 shares with
no par value
1,583,095 5,756,500 shares with
no par
value
52,389 190,500 shares
with no
par
value

Pursuant to Article 26 of the Euronext Growth Milan Issuers' Regulations, the Company hereby announces the composition of its shareholding structure, updated to the latest results in its possession:

Shareholder Number of Shares % of Share Capital % of Voting Rights
Bartolomucci Holding S.r.l. 4,000,000 67.26% 67.26%
Axon Partners Group SA 592.800 9.97% 9.97%
Invitalia S.p.A. (via Fondo 381,600 6.42% 6.42%
Cresci al Sud)
Algebris Investments 333.300 5.60% 5.60%
Market 639,300 10.75% 10.75%
TOTAL 5,947,000 100% 100%

The shareholder structure is also available in the Shareholders section of the Company's website (www.otofarmaspa.com), under Investor Relations.

***************************

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by CONSOB by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website www.otofarmaspa.com.

Identification Codes

Alphanumeric Code: OTO ISIN for Ordinary Shares: IT0005663361

***

About Otofarma SpA

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist teleaudiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

For more information:

Otofarma S.p.A.- Investor relations

Anna Incarnato Bartolomucci E-mail: [email protected] mob: +39 347 0506780

Alantra – Euronext Growth Advisor

E-mail: [email protected] mob: +39 334 6267242

SEC Newgate – Media Relations

+39 02 624 999 1 Michele Bon – [email protected] – +39 338 693 3868 Francesca Brambilla – [email protected] – +39 338 627 2146

Talk to a Data Expert

Have a question? We'll get back to you promptly.